Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data

Gilteritinib has been approved as monotherapy in adults with acute myeloid leukemia (AML) FLT3 mutated with relapsed or refractory disease, in light of its advantages in terms of survival and the favorable safety profile. Hepatobiliary disorders and musculoskeletal and connective tissue disorders re...

Descripción completa

Detalles Bibliográficos
Autores principales: Gozzo, Lucia, Nardo, Antonella, Brancati, Serena, Judica, Antongiulio, Duminuco, Andrea, Maugeri, Cinzia, Parisi, Marina, Longo, Laura, Vitale, Daniela Cristina, Ruscica, Rosy, Romano, Giovanni Luca, Mauro, Elisa, Fiumara, Paolo Fabio, Palumbo, Giuseppe Alberto Maria, Di Raimondo, Francesco, Vetro, Calogero, Drago, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218212/
https://www.ncbi.nlm.nih.gov/pubmed/37239765
http://dx.doi.org/10.3390/healthcare11101479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218212/
https://www.ncbi.nlm.nih.gov/pubmed/37239765
http://dx.doi.org/10.3390/healthcare11101479

Ejemplares similares